Neureva-Services offers in vitro and in vivo toxicity screening to help you in making “Go/No Go” decisions” from the early stages of drug development process.

In Vitro assay for neurotoxicity evaluation of leads compounds

Cellular in vitro toxicity testing of your compounds on CNS rat primary cell cultures with early cytotoxicity endpoints and minimal compound requirement.

 Neurotoxicity assay on CNS primary cell cultures

High Content Screening assay using Cellomics® imager on rat primary cortical culture:

• Quantification of neurotoxicity effects of test compounds by evaluting cell counts differences

• Determination of IC50 by detecting Map2 immunopositive surface
• High throughput analysis by qPCR

Early in vivo neurotoxicity testing

Early assessment of the neurotoxicity of a test compound can be performed in a safety approach to determine potential toxicity and to select dose for specific therapeutic activity on efficacy models.

Neurobehavioral screening

• Clinical Observation
• Modified Irwin test
• Motor activity

Neuropathology

• Brain and Spinal Cord morphometry
• Immunohistochemistry
• Image analysis

More